Article Listing - An examination of pharmaceutical systems in severely disrupted countries

DRUGS AND SWEDEN'S HEALTH BILL

6 April 1992

Sales of pharmaceutical products in Sweden totaled 10 billion krone ($1.6 billion) in 1990, an increase of 1 billion krone...

MAINTENANCE ULCER THERAPY CUT URGED

6 April 1992

A team of UK gastroenterologists have called for physicians to stop treating duodenal ulcer patients with maintenance H2 antagonist therapy....

WELLCOME SHARE FLOAT "MANAGERS"

6 April 1992

Following the recent announcement of its decision to float a further bank of shares in Wellcome plc, the Wellcome Trust...

BLOOD BANKING AND PLASMA PRODUCTS

6 April 1992

The world market for blood banking and plasma products was valued at $2.5 billion in 1990, and is expected to...

AUSTRALIAN VACCINE RESEARCH

6 April 1992

The Walter and Eliza Hall Institute of Medical research in Melbourne, Australia, is to set up a commercial joint venture...

MGI PHARMA'S SALAGEN

6 April 1992

MGI Pharma has gained orphan drug status from the US Food and Drug Administration for Salagen (pilocarpine), to treat dry...

NEW EDITOR OF D&TB

6 April 1992

Joe Collier, reader and consultant in clinical pharmacology at St George's Hospital Medical School, London, has been appointed editor of...

New Swiss Hospital Costs Program

6 April 1992

The Swiss Federal Council has come out in support of the need for severe measures to combat increasing health care...

WELLCOME SHARE FLOAT "MANAGERS"

6 April 1992

Following the recent announcement of its decision to float a further bank of shares in Wellcome plc, the Wellcome Trust...

DEPRESSION: THE COST TO SOCIETY

6 April 1992

The costs of depression to the National Health Service in the UK are L 333 million per year, according to...

Showing 94611-94620 of 95558 articles

Go to beginningPreviousNextGo to end